Table 1.
Demographic and clinical variables in patients with Mtb infection and disease.
| EPTB n = 14 | PTB N = 16 | LTBI N = 17 | |
|---|---|---|---|
| Gender, male (n, %) | 9 (64) | 13 (81) | 6 (35) |
| Age (median, range) | 30 (18–40) | 32 (18–64) | 29 (20–54) |
| Ethnicity (n, %) | |||
| Caucasian | 3 (21) | 6 (37) | 0 (0) |
| African | 8 (57) | 3 (19) | 5 (29) |
| Asian | 2 (14) | 6 (37) | 9 (52) |
| Unknown | 1 (7) | 1 (6) | 3 (18) |
| Previous TB treatment (n, %) | |||
| Yes | 1 (7) | 2 (13) | 0 (0) |
| Unknown | 2 (14) | 1 (6) | 0 (0) |
| Confirmed Mtb complex in culture/PCR (%) | |||
| Yes | 8 (57) | 13 (81) | 0 (0) |
| Resistance (%) | |||
| Monoresistant TB1 | 5 (36) | 2 (13) | |
| No of TB localizations (%) | |||
| 1 | 12 (86) | 13 (81) | |
| 2 | 2 (14) | 3 (19) | |
| Low: High symptom score2 | 7:7 | 5:11 | 16:1 |
| QuantiFERON-TB Gold (positive: negative: no data) | 12:0:2 | 9:3:4 | 17:0:0 |
| ESR3 at baseline (mm/hour, range) | 32 (5–82) | 35 (3–109) | 21 (13–40) |
| CRP3 at baseline (mg/L, range) | 17 (1–89) | 19 (0.6–97) | 3 (0.7–10) |
1Monoresistance is defined as resistance to one first-line anti-TB drug only.
2High symptom score is defined as 2 or more of the following symptoms: Fever (>38.0°), weight loss, cough, lymphadenopathy, night sweat. Low symptom score is defined as one of the symptoms listed or asymptomatic.
3ESR, erythrocyte sedimentation rate; CRP, C- reactive protein.